Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
CINECA IRIS Institutional Research Information System
Background: Diabetes is one of the leading causes of death and disability worldwide, and affects people regardless of country, age group, or sex. Using the most recent evidentiary and analytical framework from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), we produced location-specific, age-specific, and sex-specific estimates of diabetes prevalence and burden from 1990 to 2021, the proportion of type 1 and type 2 diabetes in 2021, the proportion of the type 2 diabetes burden attributable to selected risk factors, and projections of diabetes prevalence through 2050. Methods: Estimates of diabetes prevalence and burden were computed in 204 countries and territories, across 25 age groups, for males and females separately and combined; these estimates comprised lost years of healthy life, measured in disability-adjusted life-years (DALYs; defined as the sum of years of life lost [YLLs] and years lived with disability [YLDs]). We used the Cause of Death Ensemble model (CODEm) approach to estimate deaths due to diabetes, incorporating 25 666 location-years of data from vital registration and verbal autopsy reports in separate total (including both type 1 and type 2 diabetes) and type-specific models. Other forms of diabetes, including gestational and monogenic diabetes, were not explicitly modelled. Total and type 1 diabetes prevalence was estimated by use of a Bayesian meta-regression modelling tool, DisMod-MR 2.1, to analyse 1527 location-years of data from the scientific literature, survey microdata, and insurance claims; type 2 diabetes estimates were computed by subtracting type 1 diabetes from total estimates. Mortality and prevalence estimates, along with standard life expectancy and disability weights, were used to calculate YLLs, YLDs, and DALYs. When appropriate, we extrapolated estimates to a hypothetical population with a standardised age structure to allow comparison in populations with different age structures. We used the comparative risk assessment framework to estimate the risk-attributable type 2 diabetes burden for 16 risk factors falling under risk categories including environmental and occupational factors, tobacco use, high alcohol use, high body-mass index (BMI), dietary factors, and low physical activity. Using a regression framework, we forecast type 1 and type 2 diabetes prevalence through 2050 with Socio-demographic Index (SDI) and high BMI as predictors, respectively. Findings: In 2021, there were 529 million (95% uncertainty interval [UI] 500–564) people living with diabetes worldwide, and the global age-standardised total diabetes prevalence was 6·1% (5·8–6·5). At the super-region level, the highest age-standardised rates were observed in north Africa and the Middle East (9·3% [8·7–9·9]) and, at the regional level, in Oceania (12·3% [11·5–13·0]). Nationally, Qatar had the world's highest age-specific prevalence of diabetes, at 76·1% (73·1–79·5) in individuals aged 75–79 years. Total diabetes prevalence—especially among older adults—primarily reflects type 2 diabetes, which in 2021 accounted for 96·0% (95·1–96·8) of diabetes cases and 95·4% (94·9–95·9) of diabetes DALYs worldwide. In 2021, 52·2% (25·5–71·8) of global type 2 diabetes DALYs were attributable to high BMI. The contribution of high BMI to type 2 diabetes DALYs rose by 24·3% (18·5–30·4) worldwide between 1990 and 2021. By 2050, more than 1·31 billion (1·22–1·39) people are projected to have diabetes, with expected age-standardised total diabetes prevalence rates greater than 10% in two super-regions: 16·8% (16·1–17·6) in north Africa and the Middle East and 11·3% (10·8–11·9) in Latin America and Caribbean. By 2050, 89 (43·6%) of 204 countries and territories will have an age-standardised rate greater than 10%. Interpretation: Diabetes remains a substantial public health issue. Type 2 diabetes, which makes up the bulk of diabetes cases, is largely preventable and, in some cases, potentially reversible if identified and managed early in the disease course. However, all evidence indicates that diabetes prevalence is increasing worldwide, primarily due to a rise in obesity caused by multiple factors. Preventing and controlling type 2 diabetes remains an ongoing challenge. It is essential to better understand disparities in risk factor profiles and diabetes burden across populations, to inform strategies to successfully control diabetes risk factors within the context of multiple and complex drivers. Funding: Bill & Melinda Gates Foundation.
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
Ong K. L.;Stafford L. K.;McLaughlin S. A.;Boyko E. J.;Vollset S. E.;Smith A. E.;Dalton B. E.;Duprey J.;Cruz J. A.;Hagins H.;Lindstedt P. A.;Aali A.;Abate Y. H.;Abate M. D.;Abbasian M.;Abbasi-Kangevari Z.;Abbasi-Kangevari M.;ElHafeez S. A.;Abd-Rabu R.;Abdulah D. M.;Abdullah A. Y. M.;Abedi V.;Abidi H.;Aboagye R. G.;Abolhassani H.;Abu-Gharbieh E.;Abu-Zaid A.;Adane T. D.;Adane D. E.;Addo I. Y.;Adegboye O. A.;Adekanmbi V.;Adepoju A. V.;Adnani Q. E. S.;Afolabi R. F.;Agarwal G.;Aghdam Z. B.;Agudelo-Botero M.;Arriagada C. E. A.;Agyemang-Duah W.;Ahinkorah B. O.;Ahmad D.;Ahmad R.;Ahmad S.;Ahmad A.;Ahmadi A.;Ahmadi K.;Ahmed A.;Ahmed A.;Ahmed L. A.;Ahmed S. A.;Ajami M.;Akinyemi R. O.;Al Hamad H.;Al Hasan S. M. A.;AL-Ahdal T. M. A.;Alalwan T. A.;Al-Aly Z.;AlBataineh M. T.;Alcalde-Rabanal J. E.;Alemi S.;Ali H.;Alinia T.;Aljunid S. M.;Almustanyir S.;Al-Raddadi R. M.;Alvis-Guzman N.;Amare F.;Ameyaw E. K.;Amiri S.;Amusa G. A.;Andrei C. L.;Anjana R. M.;Ansar A.;Ansari G.;Ansari-Moghaddam A.;Anyasodor A. E.;Arabloo J.;Aravkin A. Y.;Areda D.;Arifin H.;Arkew M.;Armocida B.;Arnlov J.;Artamonov A. A.;Arulappan J.;Aruleba R. T.;Arumugam A.;Aryan Z.;Asemu M. T.;Asghari-Jafarabadi M.;Askari E.;Asmelash D.;Astell-Burt T.;Athar M.;Athari S. S.;Atout M. M. W.;Avila-Burgos L.;Awaisu A.;Azadnajafabad S.;Darshan B. B.;Babamohamadi H.;Badar M.;Badawi A.;Badiye A. D.;Baghcheghi N.;Bagheri N.;Bagherieh S.;Bah S.;Bahadory S.;Bai R.;Baig A. A.;Baltatu O. C.;Baradaran H. R.;Barchitta M.;Bardhan M.;Barengo N. C.;Barnighausen T. W.;Barone M. T. U.;Barone-Adesi F.;Barrow A.;Bashiri H.;Basiru A.;Basu S.;Basu S.;Batiha A. -M. M.;Batra K.;Bayih M. T.;Bayileyegn N. S.;Behnoush A. H.;Bekele A. B.;Belete M. A.;Belgaumi U. I.;Belo L.;Bennett D. A.;Bensenor I. M.;Berhe K.;Berhie A. Y.;Bhaskar S.;Bhat A. N.;Bhatti J. S.;Bikbov B.;Bilal F.;Bintoro B. S.;Bitaraf S.;Bitra V. R.;Bjegovic-Mikanovic V.;Bodolica V.;Boloor A.;Brauer M.;Brazo-Sayavera J.;Brenner H.;Butt Z. A.;Calina D.;Campos L. A.;Campos-Nonato I. R.;Cao Y.;Cao C.;Car J.;Carvalho M.;Castaneda-Orjuela C. A.;Catala-Lopez F.;Cerin E.;Chadwick J.;Chandrasekar E. K.;Chanie G. S.;Charan J.;Chattu V. K.;Chauhan K.;Cheema H. A.;Abebe E. C.;Chen S.;Cherbuin N.;Chichagi F.;Chidambaram S. B.;Cho W. C. S.;Choudhari S. G.;Chowdhury R.;Chowdhury E. K.;Chu D. -T.;Chukwu I. S.;Chung S. -C.;Coberly K.;Columbus A.;Contreras D.;Cousin E.;Criqui M. H.;Cruz-Martins N.;Cuschieri S.;Dabo B.;Dadras O.;Dai X.;Damasceno A. A. M.;Dandona R.;Dandona L.;Das S.;Dascalu A. M.;Dash N. R.;Dashti M.;Davila-Cervantes C. A.;De la Cruz-Gongora V.;Debele G. R.;Delpasand K.;Demisse F. W.;Demissie G. D.;Deng X.;Denova-Gutierrez E.;Deo S. V.;Dervisevic E.;Desai H. D.;Desale A. T.;Dessie A. M.;Desta F.;Dewan S. M. R.;Dey S.;Dhama K.;Dhimal M.;Diao N.;Diaz D.;Dinu M.;Diress M.;Djalalinia S.;Doan L. P.;Dongarwar D.;dos Santos Figueiredo F. W.;Duncan B. B.;Dutta S.;Dziedzic A. M.;Edinur H. A.;Ekholuenetale M.;Ekundayo T. C.;Elgendy I. Y.;Elhadi M.;El-Huneidi W.;Elmeligy O. A. A.;Elmonem M. A.;Endeshaw D.;Esayas H. L.;Eshetu H. B.;Etaee F.;Fadhil I.;Fagbamigbe A. F.;Fahim A.;Falahi S.;Faris M. E. M.;Farrokhpour H.;Farzadfar F.;Fatehizadeh A.;Fazli G.;Feng X.;Ferede T. Y.;Fischer F.;Flood D.;Forouhari A.;Foroumadi R.;Koudehi M. F.;Gaidhane A. M.;Gaihre S.;Gaipov A.;Galali Y.;Ganesan B.;Garcia-Gordillo M. A.;Gautam R. K.;Gebrehiwot M.;Gebrekidan K. G.;Gebremeskel T. G.;Getacher L.;Ghadirian F.;Ghamari S. -H.;Nour M. G.;Ghassemi F.;Golechha M.;Goleij P.;Golinelli D.;Gopalani S. V.;Guadie H. A.;Guan S. -Y.;Gudayu T. W.;Guimaraes R. A.;Guled R. A.;Gupta R.;Gupta K.;Gupta V. B.;Gupta V. K.;Gyawali B.;Haddadi R.;Hadi N. R.;Haile T. G.;Hajibeygi R.;Haj-Mirzaian A.;Halwani R.;Hamidi S.;Hankey G. J.;Hannan M. A.;Haque S.;Harandi H.;Harlianto N. I.;Mahmudul Hasan S. M.;Hasan S. S.;Hasani H.;Hassanipour S.;Hassen M. B.;Haubold J.;Hayat K.;Heidari G.;Heidari M.;Hessami K.;Hiraike Y.;Holla R.;Hossain S.;Hossain M. S.;Hosseini M. -S.;Hosseinzadeh M.;Hosseinzadeh H.;Huang J.;Huda M. N.;Hussain S.;Huynh H. -H.;Hwang B. -F.;Ibitoye S. E.;Ikeda N.;Ilic I. M.;Ilic M. D.;Inbaraj L. R.;Iqbal A.;Islam S. M. S.;Islam R. M.;Ismail N. E.;Iso H.;Isola G.;Itumalla R.;Iwagami M.;Iwu C. C. D.;Iyamu I. O.;Iyasu A. N.;Jacob L.;Jafarzadeh A.;Jahrami H.;Jain R.;Jaja C.;Jamalpoor Z.;Jamshidi E.;Janakiraman B.;Jayanna K.;Jayapal S. K.;Jayaram S.;Jayawardena R.;Jebai R.;Jeong W.;Jin Y.;Jokar M.;Jonas J. B.;Joseph N.;Joseph A.;Joshua C. E.;Joukar F.;Jozwiak J. J.;Kaambwa B.;Kabir A.;Kabthymer R. H.;Kadashetti V.;Kahe F.;Kalhor R.;Kandel H.;Karanth S. D.;Karaye I. M.;Karkhah S.;Katoto P. D. M. C.;Kaur N.;Kazemian S.;Kebede S. A.;Khader Y. S.;Khajuria H.;Khalaji A.;Khan M. A. B.;Khan M.;Khan A.;Khanal S.;Khatatbeh M. M.;Khater A. M.;Khateri S.;Khorashadizadeh F.;Khubchandani J.;Kibret B. G.;Kim M. S.;Kimokoti R. W.;Kisa A.;Kivimaki M.;Kolahi A. -A.;Komaki S.;Kompani F.;Koohestani H. R.;Korzh O.;Kostev K.;Kothari N.;Koyanagi A.;Krishan K.;Krishnamoorthy Y.;Defo B. K.;Kuddus M.;Kuddus M. A.;Kumar R.;Kumar H.;Kundu S.;Kurniasari M. D.;Kuttikkattu A.;Vecchia C. L.;Lallukka T.;Larijani B.;Larsson A. O.;Latief K.;Lawal B. K.;Le T. T. T.;Le T. T. B.;Lee S. W. H.;Lee M.;Lee W. -C.;Lee P. H.;Lee S. -W.;Lee S. W.;Legesse S. M.;Lenzi J.;Li Y.;Li M. -C.;Lim S. S.;Lim L. -L.;Liu X.;Liu C.;Lo C. -H.;Lopes G.;Lorkowski S.;Lozano R.;Lucchetti G.;Maghazachi A. A.;Mahasha P. W.;Mahjoub S.;Mahmoud M. A.;Mahmoudi R.;Mahmoudimanesh M.;Mai A. T.;Majeed A.;Sanaye P. M.;Makris K. C.;Malhotra K.;Malik A. A.;Malik I.;Mallhi T. H.;Malta D. C.;Mamun A. A.;Mansouri B.;Marateb H. R.;Mardi P.;Martini S.;Martorell M.;Marzo R. R.;Masoudi R.;Masoudi S.;Mathews E.;Maugeri A.;Mazzaglia G.;Mekonnen T.;Meshkat M.;Mestrovic T.;Jonasson J. M.;Miazgowski T.;Michalek I. M.;Minh L. H. N.;Mini G. K.;Miranda J. J.;Mirfakhraie R.;Mirrakhimov E. M.;Mirza-Aghazadeh-Attari M.;Misganaw A.;Misgina K. H.;Mishra M.;Moazen B.;Mohamed N. S.;Mohammadi E.;Mohammadi M.;Mohammadian-Hafshejani A.;Mohammadshahi M.;Mohseni A.;Mojiri-Forushani H.;Mokdad A. H.;Momtazmanesh S.;Monasta L.;Moniruzzaman M.;Mons U.;Montazeri F.;Ghalibaf A. M.;Moradi Y.;Moradi M.;Sarabi M. M.;Morovatdar N.;Morrison S. D.;Morze J.;Mossialos E.;Mostafavi E.;Mueller U. O.;Mulita F.;Mulita A.;Murillo-Zamora E.;Musa K. I.;Mwita J. C.;Nagaraju S. P.;Naghavi M.;Nainu F.;Nair T. S.;Najmuldeen H. H. R.;Nangia V.;Nargus S.;Naser A. Y.;Nassereldine H.;Natto Z. S.;Nauman J.;Nayak B. P.;Ndejjo R.;Negash H.;Negoi R. I.;Nguyen H. T. H.;Nguyen D. H.;Nguyen P. T.;Nguyen V. T.;Nguyen H. Q.;Niazi R. K.;Nigatu Y. T.;Ningrum D. N. A.;Nizam M. A.;Nnyanzi L. A.;Noreen M.;Noubiap J. J.;Nzoputam O. J.;Nzoputam C. I.;Oancea B.;Odogwu N. M.;Odukoya O. O.;Ojha V. A.;Okati-Aliabad H.;Okekunle A. P.;Okonji O. C.;Okwute P. G.;Olufadewa I. I.;Onwujekwe O. E.;Ordak M.;Ortiz A.;Osuagwu U. L.;Oulhaj A.;Owolabi M. O.;Padron-Monedero A.;Padubidri J. R.;Palladino R.;Panagiotakos D.;Panda-Jonas S.;Pandey A.;Pandey A.;Pandi-Perumal S. R.;Stoian A. M. P.;Pardhan S.;Parekh T.;Parekh U.;Pasovic M.;Patel J.;Patel J. R.;Paudel U.;Pepito V. C. F.;Pereira M.;Perico N.;Perna S.;Petcu I. -R.;Petermann-Rocha F. E.;Podder V.;Postma M. J.;Pourali G.;Pourtaheri N.;Prates E. J. S.;Qadir M. M. F.;Qattea I.;Raee P.;Rafique I.;Rahimi M.;Rahimifard M.;Rahimi-Movaghar V.;Rahman M. O.;Rahman M. A.;Rahman M. H. U.;Rahman M.;Rahman M. M.;Rahmani M.;Rahmani S.;Rahmanian V.;Rahmawaty S.;Rahnavard N.;Rajbhandari B.;Ram P.;Ramazanu S.;Rana J.;Rancic N.;Ranjha M. M. A. Z.;Rao C. R.;Rapaka D.;Rasali D. P.;Rashedi S.;Rashedi V.;Rashid A. M.;Rashidi M. -M.;Ratan Z. A.;Rawaf S.;Rawal L.;Redwan E. M. M.;Remuzzi G.;Rengasamy K. R. R.;Renzaho A. M. N.;Reyes L. F.;Rezaei N.;Rezaei N.;Rezaeian M.;Rezazadeh H.;Riahi S. M.;Rias Y. A.;Riaz M.;Ribeiro D.;Rodrigues M.;Rodriguez J. A. B.;Roever L.;Rohloff P.;Roshandel G.;Roustazadeh A.;Rwegerera G. M.;Saad A. M. A.;Saber-Ayad M. M.;Sabour S.;Sabzmakan L.;Saddik B.;Sadeghi E.;Saeed U.;Moghaddam S. S.;Safi S.;Safi S. Z.;Saghazadeh A.;Sharif-Askari N. S.;Sharif-Askari F. S.;Sahebkar A.;Sahoo S. S.;Sahoo H.;Saif-Ur-Rahman K. M.;Sajid M. R.;Salahi S.;Salahi S.;Saleh M. A.;Salehi M. A.;Salomon J. A.;Sanabria J.;Sanjeev R. K.;Sanmarchi F.;Santric-Milicevic M. M.;Sarasmita M. A.;Sargazi S.;Sathian B.;Sathish T.;Sawhney M.;Schlaich M. P.;Schmidt M. I.;Schuermans A.;Seidu A. -A.;Kumar N. S.;Sepanlou S. G.;Sethi Y.;Seylani A.;Shabany M.;Shafaghat T.;Shafeghat M.;Shafie M.;Shah N. S.;Shahid S.;Shaikh M. A.;Shanawaz M.;Shannawaz M.;Sharfaei S.;Shashamo B. B.;Shiri R.;Shittu A.;Shivakumar K. M.;Shivalli S.;Shobeiri P.;Shokri F.;Shuval K.;Sibhat M. M.;Silva L. M. R.;Simpson C. R.;Singh J. A.;Singh P.;Singh S.;Siraj M. S.;Skryabina A. A.;Sohag A. A. M.;Soleimani H.;Solikhah S.;Soltani-Zangbar M. S.;Somayaji R.;Sorensen R. J. D.;Starodubova A. V.;Sujata S.;Suleman M.;Sun J.;Sundstrom J.;Tabares-Seisdedos R.;Tabatabaei S. M.;Tabatabaeizadeh S. -A.;Tabish M.;Taheri M.;Taheri E.;Taki E.;Tamuzi J. J. L. L.;Tan K. -K.;Tat N. Y.;Taye B. T.;Temesgen W. A.;Temsah M. -H.;Tesler R.;Thangaraju P.;Thankappan K. R.;Thapa R.;Tharwat S.;Thomas N.;Ticoalu J. H. V.;Tiyuri A.;Tonelli M.;Tovani-Palone M. R.;Trico D.;Trihandini I.;Tripathy J. P.;Tromans S. J.;Tsegay G. M.;Tualeka A. R.;Tufa D. G.;Tyrovolas S.;Ullah S.;Upadhyay E.;Vahabi S. M.;Vaithinathan A. G.;Valizadeh R.;van Daalen K. R.;Vart P.;Varthya S. B.;Vasankari T. J.;Vaziri S.;Verma M. V.;Verras G. -I.;Vo D. C.;Wagaye B.;Waheed Y.;Wang Z.;Wang Y.;Wang C.;Wang F.;Wassie G. T.;Wei M. Y. W.;Weldemariam A. H.;Westerman R.;Wickramasinghe N. D.;Wu Y.;Wulandari R. D. W. I.;Xia J.;Xiao H.;Xu S.;Xu X.;Yada D. Y.;Yang L.;Yatsuya H.;Yesiltepe M.;Yi S.;Yohannis H. K.;Yonemoto N.;You Y.;Zaman S. B.;Zamora N.;Zare I.;Zarea K.;Zarrintan A.;Zastrozhin M. S.;Zeru N. G.;Zhang Z. -J.;Zhong C.;Zhou J.;Zielinska M.;Zikarg Y. T.;Zodpey S.;Zoladl M.;Zou Z.;Zumla A.;Zuniga Y. M. H.;Magliano D. J.;Murray C. J. L.;Hay S. I.;Vos T.
2023-01-01
Abstract
Background: Diabetes is one of the leading causes of death and disability worldwide, and affects people regardless of country, age group, or sex. Using the most recent evidentiary and analytical framework from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), we produced location-specific, age-specific, and sex-specific estimates of diabetes prevalence and burden from 1990 to 2021, the proportion of type 1 and type 2 diabetes in 2021, the proportion of the type 2 diabetes burden attributable to selected risk factors, and projections of diabetes prevalence through 2050. Methods: Estimates of diabetes prevalence and burden were computed in 204 countries and territories, across 25 age groups, for males and females separately and combined; these estimates comprised lost years of healthy life, measured in disability-adjusted life-years (DALYs; defined as the sum of years of life lost [YLLs] and years lived with disability [YLDs]). We used the Cause of Death Ensemble model (CODEm) approach to estimate deaths due to diabetes, incorporating 25 666 location-years of data from vital registration and verbal autopsy reports in separate total (including both type 1 and type 2 diabetes) and type-specific models. Other forms of diabetes, including gestational and monogenic diabetes, were not explicitly modelled. Total and type 1 diabetes prevalence was estimated by use of a Bayesian meta-regression modelling tool, DisMod-MR 2.1, to analyse 1527 location-years of data from the scientific literature, survey microdata, and insurance claims; type 2 diabetes estimates were computed by subtracting type 1 diabetes from total estimates. Mortality and prevalence estimates, along with standard life expectancy and disability weights, were used to calculate YLLs, YLDs, and DALYs. When appropriate, we extrapolated estimates to a hypothetical population with a standardised age structure to allow comparison in populations with different age structures. We used the comparative risk assessment framework to estimate the risk-attributable type 2 diabetes burden for 16 risk factors falling under risk categories including environmental and occupational factors, tobacco use, high alcohol use, high body-mass index (BMI), dietary factors, and low physical activity. Using a regression framework, we forecast type 1 and type 2 diabetes prevalence through 2050 with Socio-demographic Index (SDI) and high BMI as predictors, respectively. Findings: In 2021, there were 529 million (95% uncertainty interval [UI] 500–564) people living with diabetes worldwide, and the global age-standardised total diabetes prevalence was 6·1% (5·8–6·5). At the super-region level, the highest age-standardised rates were observed in north Africa and the Middle East (9·3% [8·7–9·9]) and, at the regional level, in Oceania (12·3% [11·5–13·0]). Nationally, Qatar had the world's highest age-specific prevalence of diabetes, at 76·1% (73·1–79·5) in individuals aged 75–79 years. Total diabetes prevalence—especially among older adults—primarily reflects type 2 diabetes, which in 2021 accounted for 96·0% (95·1–96·8) of diabetes cases and 95·4% (94·9–95·9) of diabetes DALYs worldwide. In 2021, 52·2% (25·5–71·8) of global type 2 diabetes DALYs were attributable to high BMI. The contribution of high BMI to type 2 diabetes DALYs rose by 24·3% (18·5–30·4) worldwide between 1990 and 2021. By 2050, more than 1·31 billion (1·22–1·39) people are projected to have diabetes, with expected age-standardised total diabetes prevalence rates greater than 10% in two super-regions: 16·8% (16·1–17·6) in north Africa and the Middle East and 11·3% (10·8–11·9) in Latin America and Caribbean. By 2050, 89 (43·6%) of 204 countries and territories will have an age-standardised rate greater than 10%. Interpretation: Diabetes remains a substantial public health issue. Type 2 diabetes, which makes up the bulk of diabetes cases, is largely preventable and, in some cases, potentially reversible if identified and managed early in the disease course. However, all evidence indicates that diabetes prevalence is increasing worldwide, primarily due to a rise in obesity caused by multiple factors. Preventing and controlling type 2 diabetes remains an ongoing challenge. It is essential to better understand disparities in risk factor profiles and diabetes burden across populations, to inform strategies to successfully control diabetes risk factors within the context of multiple and complex drivers. Funding: Bill & Melinda Gates Foundation.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14085/20225
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
Citazioni
ND
1467
1217
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.
Errore
Errore
Informativa cookie
Utilizziamo cookie di prima e di terza parte per garantire la funzionalità del sito e per mostrare "le citazioni sociali (PLUMX)", "le pubblicazioni suggerite (core recommender)", "il grafico delle citazioni" e "le licenze dei fulltext". I Cookie di terze parti sono disattivati di default salvo esplicito consenso (Accetta tutti).
Preferenze cookie
Utilizzo dei cookie?
Utilizziamo i cookie per consentire il funzionamento del sito e per migliorare la tua esperienza online. Puoi scegliere per ogni categoria se abilitarli/disabilitarli quando vuoi. Per maggiori dettagli relativi ai cookie ed altri dati sensibili, puoi leggere la cookie policy e la privacy policy integrale.
Questi cookie sono essenziali per il funzionamento del nostro sito. Senza questi cookie, il sito potrebbe non funzionare correttamente.
Questi cookie consentono al sito di ricordare le scelte che hai eseguito in precedenza
Nome
Dominio
Durata
Descrizione
_pk.*
matomo.valueforyou.cineca.it
sessione
permette il tracciamento delle scelte fatte dall'utente
Questi cookie consentono al sito di accedere a funzionalità esterne
Nome
Dominio
Durata
Descrizione
s_.*
plu.mx
sessione
recupero grafico citazioni sociali da plumx
A_.*
core.ac.uk
7 giorni
recupero pubblicazioni consigliate per il pannello core-recommander
GS_.*
gstatic.com
richiesta http
visualizza grafico citazioni
CC_.*
creativecommons.org
richiesta http
visualizza licenza bitstream
Maggiori informazioni
Per qualsiasi domanda in relazione alle nostre policy sui cookie e sulle tue scelte, puoi visualizzare l'informativa completa a questo url.